489 related articles for article (PubMed ID: 25596769)
41. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models.
Ghosh S; Krege W; Doerr B; Mischnik M; Pragst I; Dickneite G; Herzog E
PLoS One; 2021; 16(10):e0258192. PubMed ID: 34614035
[TBL] [Abstract][Full Text] [Related]
42. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.
Lambourne MD; Eltringham-Smith LJ; Gataiance S; Arnold DM; Crowther MA; Sheffield WP
J Thromb Haemost; 2012 Sep; 10(9):1830-40. PubMed ID: 22817470
[TBL] [Abstract][Full Text] [Related]
43. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
[TBL] [Abstract][Full Text] [Related]
44. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
45. A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions.
Ogawa S; Szlam F; Ohnishi T; Molinaro RJ; Hosokawa K; Tanaka KA
Thromb Haemost; 2011 Dec; 106(6):1215-23. PubMed ID: 22071880
[TBL] [Abstract][Full Text] [Related]
46. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
Dickneite G
Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
[TBL] [Abstract][Full Text] [Related]
47. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
Zhou W; Schwarting S; Illanes S; Liesz A; Middelhoff M; Zorn M; Bendszus M; Heiland S; van Ryn J; Veltkamp R
Stroke; 2011 Dec; 42(12):3594-9. PubMed ID: 21998060
[TBL] [Abstract][Full Text] [Related]
48. Bleeding and antidotes in new oral anticoagulants.
Majeed A; Schulman S
Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
[TBL] [Abstract][Full Text] [Related]
49. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
[TBL] [Abstract][Full Text] [Related]
50. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects.
Sørensen B; Johansen P; Nielsen GL; Sørensen JC; Ingerslev J
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):469-77. PubMed ID: 12851533
[TBL] [Abstract][Full Text] [Related]
51. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
[TBL] [Abstract][Full Text] [Related]
52. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
Escolar G; Arellano-Rodrigo E; Lopez-Vilchez I; Molina P; Sanchis J; Reverter JC; Carne X; Cid J; Villalta J; Tassies D; Galan AM; Diaz-Ricart M
Circ J; 2015; 79(2):331-8. PubMed ID: 25482382
[TBL] [Abstract][Full Text] [Related]
53. Ticagrelor reversal:
Calmette L; Martin AC; Le Bonniec B; Zlotnik D; Gouin-Thibault I; Bachelot-Loza C; Gaussem P; Godier A
J Clin Pathol; 2017 Sep; 70(9):733-739. PubMed ID: 28159767
[TBL] [Abstract][Full Text] [Related]
54. Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis.
Arellano-Rodrigo E; Fernandez-Gallego V; López-Vilchez I; Molina P; Díaz-Ricart M; Zafar MU; Badimon JJ; van Ryn J; Escolar G
Transfusion; 2019 Jul; 59(7):2436-2445. PubMed ID: 30946491
[TBL] [Abstract][Full Text] [Related]
55. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
57. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
Tanaka KA; Szlam F; Dickneite G; Levy JH
Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
[TBL] [Abstract][Full Text] [Related]
58. In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.
Mazzeffi M; Szlam F; Jakubowski JA; Tanaka KA; Sugidachi A; Levy JH
Thromb Res; 2013 Jul; 132(1):106-11. PubMed ID: 23664633
[TBL] [Abstract][Full Text] [Related]
59. The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine.
Davis PK; Musunuru H; Walsh M; Mitra R; Ploplis V; Castellino FJ
Thromb Haemost; 2012 Sep; 108(3):586-8. PubMed ID: 22782135
[No Abstract] [Full Text] [Related]
60. Recombinant human prothrombin reduced blood loss in a porcine model of dilutional coagulopathy with uncontrolled bleeding.
Hansson KM; Johansson KJ; Wingren C; Fries D; Nelander K; Lövgren A
Blood Coagul Fibrinolysis; 2017 Apr; 28(3):244-253. PubMed ID: 27428015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
